John Hamer is the Managing General Partner of DCVC Bio, a $250M life science venture fund that invests at. See sector focus and contact routes.
John Hamer is the Managing General Partner of DCVC Bio, a $250M life science venture fund that invests at the intersection of artificial intelligence and the life sciences, with over a decade of experience in San Francisco Bay Area life science VC. His investment thesis targets companies leveraging deep neural networks, machine vision, and advanced robotics to accelerate medicine discovery or transform agriculture, focusing on the AI–life sciences interface. Hamer typically leads investments in the $5.0M–$25.0M range, with a sweet spot around $15.0M, and is recorded as a lead investor in 17 deals. Notable portfolio companies include Atomwise, which uses deep neural networks for small-molecule drug discovery, and Blue River Technologies, acquired by John Deere for its pesticide-reducing robotics. He also holds a directorship at Alchemab Therapeutics Ltd, a London-based active company. Hamer’s distinctive background includes serving as CEO of Arête Therapeutics and Paradigm Genetics, plus a prior career as a Full Professor of Biological Sciences at Purdue University where he was a Packard and NSF Presidential Faculty Fellow.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like John Hamer · Full investor directory · Investor access · Company funding database